Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Standout Stocks Under $10 With 86% Upside Potential or More

As the chances for a September rate cut grow even stronger, these three penny stocks can emerge as substantial wealth creators.

AMZN : 186.43 (-0.24%)
AAPL : 220.69 (+1.80%)
NVDA : 113.37 (-1.92%)
OPAL : 3.70 (+1.37%)
OCUL : 9.05 (+3.31%)
NUVB : 2.90 (-5.54%)
Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix: Q1 Earnings Snapshot

OCUL : 9.05 (+3.31%)
2 Small-Cap Growth Stocks With Room To Run

These two small-cap growth stocks could be ready to run.

REGN : 1,138.81 (-0.69%)
RHHBY : 39.6100 (+0.71%)
ACHR : 3.06 (-2.24%)
OCUL : 9.05 (+3.31%)
Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix: Q4 Earnings Snapshot

OCUL : 9.05 (+3.31%)
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.

BIIB : 197.59 (-0.31%)
XBI : 100.81 (-0.14%)
XLK : 217.17 (-0.91%)
OCUL : 9.05 (+3.31%)
LRMR : 6.85 (+0.59%)
Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 9.05 (+3.31%)
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

/PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical,...

OCUL : 9.05 (+3.31%)
Ocular Therapeutix: Q2 Earnings Snapshot

Ocular Therapeutix: Q2 Earnings Snapshot

OCUL : 9.05 (+3.31%)
Stocks Set to Open Higher as Investors Await Fed Meeting, Inflation Data

June S&P 500 futures (ESM23) are up +0.23%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.46% this morning as market participants looked ahead to the latest U.S. inflation data and the Federal Reserve’s...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 227.20 (-0.29%)
GM : 48.66 (+2.40%)
ADBE : 508.13 (-1.34%)
NFLX : 690.47 (-2.33%)
TGT : 153.60 (+1.08%)
CMA : 59.70 (+2.02%)
ZION : 47.01 (+0.19%)
ADS.D.DX : 220.650 (-0.45%)
NOVN.Z.IX : 97.960 (+0.01%)
GF.Z.IX : 62.650 (-1.03%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar